These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1678 related articles for article (PubMed ID: 27473820)

  • 1. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
    Roskoski R
    Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
    Roskoski R
    Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
    Roskoski R
    Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
    Treliński J; Robak T
    Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective JAK inhibitors in development for rheumatoid arthritis.
    Norman P
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1067-77. PubMed ID: 24818516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.
    Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W
    Front Immunol; 2022; 13():884399. PubMed ID: 35693820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
    Dymock BW; See CS
    Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The promise of Janus kinase inhibitors in the treatment of hematological malignancies.
    Senkevitch E; Durum S
    Cytokine; 2017 Oct; 98():33-41. PubMed ID: 28277287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.
    Kettle JG; Åstrand A; Catley M; Grimster NP; Nilsson M; Su Q; Woessner R
    Expert Opin Ther Pat; 2017 Feb; 27(2):127-143. PubMed ID: 27774824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Properties of FDA-approved small molecule protein kinase inhibitors.
    Roskoski R
    Pharmacol Res; 2019 Jun; 144():19-50. PubMed ID: 30877063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
    Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
    J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK: Not Just Another Kinase.
    Agashe RP; Lippman SM; Kurzrock R
    Mol Cancer Ther; 2022 Dec; 21(12):1757-1764. PubMed ID: 36252553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.
    Constantinescu SN; Leroy E; Gryshkova V; Pecquet C; Dusa A
    Biochem Soc Trans; 2013 Aug; 41(4):1048-54. PubMed ID: 23863177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors.
    Kim HO
    Arch Pharm Res; 2020 Nov; 43(11):1173-1186. PubMed ID: 33161563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.
    Saharinen P; Silvennoinen O
    J Biol Chem; 2002 Dec; 277(49):47954-63. PubMed ID: 12351625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology.
    Cinats A; Heck E; Robertson L
    Skin Therapy Lett; 2018 May; 23(3):5-9. PubMed ID: 29772037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.
    Hammarén HM; Ungureanu D; Grisouard J; Skoda RC; Hubbard SR; Silvennoinen O
    Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4642-7. PubMed ID: 25825724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A historical overview of protein kinases and their targeted small molecule inhibitors.
    Roskoski R
    Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advance in bone destruction participated by JAK/STAT in rheumatoid arthritis and therapeutic effect of JAK/STAT inhibitors.
    Hu L; Liu R; Zhang L
    Int Immunopharmacol; 2022 Oct; 111():109095. PubMed ID: 35926270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 84.